Apellis Pharmaceuticals said it has received approval from the Food and Drug Administration for Empaveli, its treatment for rare kidney diseases.

Proven efficacy across all three key markers of disease-68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Broad label includes adults and ...

Related: FDA eliminates 52 food standards in sweeping deregulation move Then one weekend, I was visiting my niece and nephew. They were showing me their snack stash and pulled out one of the new ...

Shares of beleaguered drugmaker Sarepta Therapeutics jumped in afterhours trading Monday after the company said it would ...